MTHFD1L Genotype

Your folate metabolism is one of the quietest engines in your biology. It builds DNA, supports recycling of a compound called homocysteine, and supports brain development from before birth into old age. A single inherited variant in the MTHFD1L (methylenetetrahydrofolate dehydrogenase 1-like) gene can subtly shift how well this engine runs.

This test reads your genotype at specific spots in MTHFD1L that research has linked to neural tube defects, late-onset Alzheimer's disease, and prognosis after coronary events. It is a one-time test of inherited DNA, and the result you get at 30 is the same one you would get at 70.

What MTHFD1L Actually Does

MTHFD1L codes for an enzyme that lives inside mitochondria, the energy-producing compartments of your cells. The enzyme produces a small molecule called formate from a folate-derived precursor (10-formyl-tetrahydrofolate). That formate is then exported out of the mitochondria, where it feeds the one-carbon pool that eventually supports the methyl cycle, including the conversion of homocysteine back into methionine. Methionine is a building block your body uses for hundreds of methylation reactions (chemical tagging that turns genes and proteins on or off).

When this upstream supply runs slowly, the downstream methyl cycle can struggle and homocysteine levels can rise. Elevated homocysteine has been implicated in Alzheimer's disease, cardiovascular disease, and birth defects in human studies, which is why variants that perturb this pathway have drawn research interest.

Late-Onset Alzheimer's Disease Risk

One of the most replicated findings involves a variant called rs11754661. A genome-wide study of 5,373 people identified the A allele as a chromosome 6 signal for late-onset Alzheimer's disease, pointing toward folate pathway abnormalities as a contributor to dementia risk.

The association has been reproduced in additional populations. In a Northern Han Chinese sample of 1,189 people, rs11754661 was associated with late-onset Alzheimer's with an odds ratio of about 1.73 (roughly 73% higher odds in carriers compared with non-carriers). A separate review of global Alzheimer's variants reported an effect estimate of 2.10 (95% CI 1.67 to 2.64) for this variant, meaning carriers had roughly twice the odds of disease. Replication has not been universal: a Spanish study of 2,467 individuals found no association between rs11754661 and Alzheimer's disease, so the effect appears stronger in some populations than others.

A nearby variant, rs2073067, sits close enough to rs11754661 to be inherited together. Its link to Alzheimer's appears strongest in people who also carry APOE ε4, the best-established genetic risk allele for late-onset dementia. This is one reason MTHFD1L results are most informative when read alongside APOE.

Familial Alzheimer's

Beyond common variants, rare changes in MTHFD1L have surfaced in family studies. In a multigenerational Colombian family, a rare missense variant (R564H) segregated with Alzheimer's disease in an oligogenic pattern, meaning it appeared to act together with other genetic changes rather than alone. Structural modeling suggested the variant subtly alters the enzyme's shape and function.

Neural Tube Defects

A different MTHFD1L variant, rs3832406, affects how the gene's instructions are spliced together before becoming a working enzyme. In an Irish population study, one form of this variant (allele 2) was protective against neural tube defects in offspring, while another form (allele 1) raised risk. This is the same category of birth defect that folic acid supplementation in pregnancy is designed to prevent.

Coronary Heart Disease and Survival

A separate variant, rs6922269, has been studied for prognosis after a heart attack. In 1,940 patients followed after acute coronary syndromes, those with the AA genotype had poorer survival over about four years, and the association held up after adjusting for age, sex, ethnicity, prior heart attack, hypertension, physical activity, statin and beta-blocker use, and BNP levels. AA carriers also had lower active vitamin B12 and higher creatinine at baseline.

The same variant did not predict survival in an independent cohort of 842 post-heart-attack patients followed for a median of 8.8 years, and a separate analysis of more than 6,000 additional coronary patients also failed to replicate the link. The authors concluded that rs6922269 is an inconsistent prognostic marker, useful for research but not for routine clinical risk stratification.

Orofacial Clefts

A rare missense MTHFD1L variant, rs143492706, was identified in an Indonesian study of non-syndromic orofacial clefts and was computationally predicted to be deleterious. This finding adds MTHFD1L to a small list of folate-pathway genes potentially involved in cleft development, but the evidence is preliminary and comes from a small case series.

Mood and Rumination

In a European sample of 2,204 adults, the rs11754661 A allele was associated with a ruminative response style, a cognitive pattern of getting stuck on negative thoughts that raises depression risk. The folate-pathway connection here is the same: methylation chemistry influences neurotransmitter synthesis, and small genetic shifts can nudge mood-related traits.

One-Time Test, Lifetime of Use

Because this is a fixed germline genotype, you do not retest it. The value comes from how you act on the result over years, not from repeating the test. If you carry a higher-risk allele at rs11754661 or rs2073067, the actionable response is to track downstream phenotypes more aggressively: get baseline homocysteine and active B12, follow APOE status, and monitor cognitive and cardiovascular markers on a regular cadence.

A reasonable schedule for that companion testing is a baseline check now, a retest in three to six months if you change your B vitamin intake or other interventions, and at least annually thereafter. The MTHFD1L result itself does not move; the things you can change in response to it do.

When Results Can Be Misleading

Genetic tests are powerful but bounded by what the assay was designed to detect. Several factors can shift how to read a result:

• Variant panel coverage: this test reports specific MTHFD1L variants the assay is built to find. A result that does not flag a risk allele does not rule out other rare changes elsewhere in the gene that the panel does not interrogate.
• Ancestry-specific allele frequencies: rs11754661 risk estimates have been measured most in European and Han Chinese populations, and at least one Spanish cohort found no association, so the clinical meaning of a result depends in part on which population the published risk estimates were derived from.
• Variants of uncertain significance: in very large gene panels (more than 200 genes), up to about 76% of reported variants in some studies have been classified as uncertain; this rate is much lower for targeted single-gene assays. If your report flags a VUS, it means the lab found a change whose effect is not yet known, not that you carry a confirmed risk allele.
• Partial penetrance: carrying a higher-risk MTHFD1L allele raises odds, it does not guarantee disease. Most carriers do not develop Alzheimer's, neural tube defects in their children, or premature coronary events.

Decision Pathway for an Out-of-Pattern Result

If your MTHFD1L result flags a higher-risk allele, the next step is not to retest MTHFD1L. It is to expand the picture around the gene's downstream pathway. Pair the genotype with homocysteine, active vitamin B12, folate, and APOE genotype. If homocysteine is elevated and B12 or folate is low, that combination is actionable through nutritional intervention and is worth discussing with a clinician.

A confirmatory test by a different method (such as Sanger sequencing) is rarely needed for well-characterized common variants but may be warranted if a rare variant is flagged unexpectedly. A genetic counselor can help interpret combined APOE plus MTHFD1L results, especially before sharing them with biological family members who may want to consider testing themselves.

Why the Counterintuitive Findings Make Sense

The same MTHFD1L variant (rs11754661) raises Alzheimer's odds in some populations but shows inconsistent effects on other outcomes. This is not a contradiction. MTHFD1L sits at a metabolic crossroads, feeding formate into the broader one-carbon pool, and its effect on any single disease depends on the rest of your folate intake, your B12 status, your APOE genotype, and your age. Genes upstream of a multi-input pathway rarely produce uniform effects across every downstream condition.